1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
LeBien, T.W. and T.F. Tedder, B lymphocytes: how they develop and function. Blood, 2008.
112(5): p. 1570-80 DOI: 10.1182/blood-2008-02-078071.
Embgenbroich, M. and S. Burgdorf, Current Concepts of Antigen Cross-Presentation. Front
Immunol, 2018. 9: p. 1643 DOI: 10.3389/fimmu.2018.01643.
Stebegg, M., et al., Regulation of the Germinal Center Response. Front Immunol, 2018. 9: p.
2469 DOI: 10.3389/fimmu.2018.02469.
Schroeder, H.W., Jr. and L. Cavacini, Structure and function of immunoglobulins. J Allergy
Clin Immunol, 2010. 125(2 Suppl 2): p. S41-52 DOI: 10.1016/j.jaci.2009.09.046.
Gutzeit, C., K. Chen, and A. Cerutti, The enigmatic function of IgD: some answers at last.
2018. 48(7): p. 1101-1113 DOI: 10.1002/eji.201646547.
Bakema, J.E. and M. van Egmond, Immunoglobulin A: A next generation of therapeutic
antibodies? MAbs, 2011. 3(4): p. 352-61 DOI: 10.4161/mabs.3.4.16092.
Pabst, O. and E. Slack, IgA and the intestinal microbiota: the importance of being specific.
Mucosal Immunol, 2020. 13(1): p. 12-21 DOI: 10.1038/s41385-019-0227-4.
Wu, L.C. and A.A. Zarrin, The production and regulation of IgE by the immune system. Nat
Rev Immunol, 2014. 14(4): p. 247-59 DOI: 10.1038/nri3632.
Bagatini, M.D., et al., Immune System and Chronic Diseases. 2017. 2017: p. 4284327 DOI:
10.1155/2017/4284327.
Dondelinger, M., et al., Understanding the Significance and Implications of Antibody
Numbering and Antigen-Binding Surface/Residue Definition. Front Immunol, 2018. 9: p. 2278
DOI: 10.3389/fimmu.2018.02278.
Schatz, D.G. and Y. Ji, Recombination centres and the orchestration of V(D)J recombination.
Nat Rev Immunol, 2011. 11(4): p. 251-63 DOI: 10.1038/nri2941.
Roth, D.B., V(D)J Recombination: Mechanism, Errors, and Fidelity. Microbiol Spectr, 2014.
2(6) DOI: 10.1128/microbiolspec.MDNA3-0041-2014.
Volpe, J.M. and T.B. Kepler, Large-scale analysis of human heavy chain V(D)J recombination
patterns. Immunome Res, 2008. 4: p. 3 DOI: 10.1186/1745-7580-4-3.
Vettermann, C. and M.S. Schlissel, Allelic exclusion of immunoglobulin genes: models and
mechanisms. Immunol Rev, 2010. 237(1): p. 22-42 DOI: 10.1111/j.1600-065X.2010.00935.x.
Vidarsson, G., G. Dekkers, and T. Rispens, IgG subclasses and allotypes: from structure to
effector functions. Front Immunol, 2014. 5: p. 520 DOI: 10.3389/fimmu.2014.00520.
Mankarious, S., et al., The half-lives of IgG subclasses and specific antibodies in patients with
primary immunodeficiency who are receiving intravenously administered immunoglobulin. J
Lab Clin Med, 1988. 112(5): p. 634-40.
de Taeye, S.W., T. Rispens, and G. Vidarsson, The Ligands for Human IgG and Their Effector
Functions. 2019. 8(2) DOI: 10.3390/antib8020030.
Sasaki, T., et al., Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in
IgG4-related disease. Int Immunol, 2020. 32(3): p. 163-174 DOI: 10.1093/intimm/dxz073.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Wang, W., et al., NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer
Immunotherapy. Front Immunol, 2015. 6: p. 368 DOI: 10.3389/fimmu.2015.00368.
Reis, E.S., et al., Complement in cancer: untangling an intricate relationship. Nat Rev
Immunol, 2018. 18(1): p. 5-18 DOI: 10.1038/nri.2017.97.
Song, E.S., K. Young, and D.W. Sears, Rat and human natural killers exhibit contrasting
immunoglobulin G subclass specificities in antibody-dependent cellular cytotoxicity reflecting
differences in their Fc receptors (Fc gamma R). J Leukoc Biol, 1990. 48(6): p. 524-30 DOI:
10.1002/jlb.48.6.524.
Miyatake, T., et al., Complement-fixing elicited antibodies are a major component in the
pathogenesis of xenograft rejection. J Immunol, 1998. 160(8): p. 4114-23.
Abès, R. and J.L. Teillaud, Impact of Glycosylation on Effector Functions of Therapeutic IgG.
Pharmaceuticals (Basel), 2010. 3(1): p. 146-157 DOI: 10.3390/ph3010146.
Kuhn, C. and H.L. Weiner, Therapeutic anti-CD3 monoclonal antibodies: from bench to
bedside. Immunotherapy, 2016. 8(8): p. 889-906 DOI: 10.2217/imt-2016-0049.
Lu, R.M., et al., Development of therapeutic antibodies for the treatment of diseases. J Biomed
Sci, 2020. 27(1): p. 1 DOI: 10.1186/s12929-019-0592-z.
Salfeld, J.G., Isotype selection in antibody engineering. Nat Biotechnol, 2007. 25(12): p.
1369-72 DOI: 10.1038/nbt1207-1369.
Niwa, R., et al., Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced
antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia
and lymphoma. Cancer Res, 2004. 64(6): p. 2127-33 DOI: 10.1158/0008-5472.can-03-2068.
Idusogie, E.E., et al., Mapping of the C1q binding site on rituxan, a chimeric antibody with a
human IgG1 Fc. J Immunol, 2000. 164(8): p. 4178-84 DOI: 10.4049/jimmunol.164.8.4178.
Yang, X. and A. Ambrogelly, Enlarging the repertoire of therapeutic monoclonal antibodies
platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific
antibodies. Curr Opin Biotechnol, 2014. 30: p. 225-9 DOI: 10.1016/j.copbio.2014.09.001.
Schlothauer, T., et al., Novel human IgG1 and IgG4 Fc-engineered antibodies with completely
abolished immune effector functions. Protein Eng Des Sel, 2016. 29(10): p. 457-466 DOI:
10.1093/protein/gzw040.
Kasli, I.M., O.R.T. Thomas, and T.W. Overton, Use of a design of experiments approach to
optimise production of a recombinant antibody fragment in the periplasm of Escherichia coli:
selection of signal peptide and optimal growth conditions. AMB Express, 2019. 9(1): p. 5
DOI: 10.1186/s13568-018-0727-8.
Ahmad, Z.A., et al., scFv antibody: principles and clinical application. Clin Dev Immunol,
2012. 2012: p. 980250 DOI: 10.1155/2012/980250.
Chiu, M.L., et al., Antibody Structure and Function: The Basis for Engineering Therapeutics.
Antibodies (Basel), 2019. 8(4) DOI: 10.3390/antib8040055.
Svozil, J. and K. Baerenfaller, A Cautionary Tale on the Inclusion of Variable
Posttranslational Modifications in Database-Dependent Searches of Mass Spectrometry Data.
Methods Enzymol, 2017. 586: p. 433-452 DOI: 10.1016/bs.mie.2016.11.007.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Pavon, J.A., et al., Selective Tryptophan Oxidation of Monoclonal Antibodies: Oxidative
Stress and Modeling Prediction. Anal Chem, 2019. 91(3): p. 2192-2200 DOI:
10.1021/acs.analchem.8b04768.
Gaza-Bulseco, G., et al., Effect of methionine oxidation of a recombinant monoclonal antibody
on the binding affinity to protein A and protein G. J Chromatogr B Analyt Technol Biomed
Life Sci, 2008. 870(1): p. 55-62 DOI: 10.1016/j.jchromb.2008.05.045.
Zarrineh, M., et al., Mechanism of antibodies purification by protein A. Anal Biochem, 2020.
609: p. 113909 DOI: 10.1016/j.ab.2020.113909.
Bailey, L.J., et al., Applications for an engineered Protein-G variant with a pH controllable
affinity to antibody fragments. J Immunol Methods, 2014. 415: p. 24-30 DOI:
10.1016/j.jim.2014.10.003.
Hong, P., S. Koza, and E.S. Bouvier, Size-Exclusion Chromatography for the Analysis of
Protein Biotherapeutics and their Aggregates. J Liq Chromatogr Relat Technol, 2012. 35(20):
p. 2923-2950 DOI: 10.1080/10826076.2012.743724.
Liu, H.F., et al., Recovery and purification process development for monoclonal antibody
production. MAbs, 2010. 2(5): p. 480-99 DOI: 10.4161/mabs.2.5.12645.
Li, F., et al., Cell culture processes for monoclonal antibody production. MAbs, 2010. 2(5): p.
466-79 DOI: 10.4161/mabs.2.5.12720.
Noh, S.M., S. Shin, and G.M. Lee, Comprehensive characterization of glutamine synthetasemediated selection for the establishment of recombinant CHO cells producing monoclonal
antibodies. Sci Rep, 2018. 8(1): p. 5361 DOI: 10.1038/s41598-018-23720-9.
Li, J., et al., A comparative study of different vector designs for the mammalian expression of
recombinant IgG antibodies. J Immunol Methods, 2007. 318(1-2): p. 113-24 DOI:
10.1016/j.jim.2006.10.010.
Vaisman-Mentesh, A., et al., The Molecular Mechanisms That Underlie the Immune Biology
of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Frontiers
in Immunology, 2020. 11 DOI: 10.3389/fimmu.2020.01951.
Almagro, J.C. and J. Fransson, Humanization of antibodies. Front Biosci, 2008. 13: p. 161933 DOI: 10.2741/2786.
Osborn, M.J., et al., High-affinity IgG antibodies develop naturally in Ig-knockout rats
carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region. J Immunol, 2013.
190(4): p. 1481-90 DOI: 10.4049/jimmunol.1203041.
Lee, E.C., et al., Complete humanization of the mouse immunoglobulin loci enables efficient
therapeutic antibody discovery. Nat Biotechnol, 2014. 32(4): p. 356-63 DOI:
10.1038/nbt.2825.
Bates, A. and C.A. Power, David vs. Goliath: The Structure, Function, and Clinical Prospects
of Antibody Fragments. Antibodies (Basel), 2019. 8(2) DOI: 10.3390/antib8020028.
Weatherill, E.E., et al., Towards a universal disulphide stabilised single chain Fv format:
importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des
Sel, 2012. 25(7): p. 321-9 DOI: 10.1093/protein/gzs021.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Benschop, R.J., et al., Development of tibulizumab, a tetravalent bispecific antibody targeting
BAFF and IL-17A for the treatment of autoimmune disease. MAbs, 2019. 11(6): p. 1175-1190
DOI: 10.1080/19420862.2019.1624463.
Cao, M., et al., Characterization and analysis of scFv-IgG bispecific antibody size variants.
MAbs, 2018. 10(8): p. 1236-1247 DOI: 10.1080/19420862.2018.1505398.
Croasdale, R., et al., Development of tetravalent IgG1 dual targeting IGF-1R-EGFR
antibodies with potent tumor inhibition. Arch Biochem Biophys, 2012. 526(2): p. 206-18 DOI:
10.1016/j.abb.2012.03.016.
DiGiandomenico, A., et al., A multifunctional bispecific antibody protects against
Pseudomonas aeruginosa. Sci Transl Med, 2014. 6(262): p. 262ra155 DOI:
10.1126/scitranslmed.3009655.
Santich, B.H., et al., Interdomain spacing and spatial configuration drive the potency of IgG[L]-scFv T cell bispecific antibodies. Sci Transl Med, 2020. 12(534) DOI:
10.1126/scitranslmed.aax1315.
Digiammarino, E.L., et al., Ligand association rates to the inner-variable-domain of a dualvariable-domain immunoglobulin are significantly impacted by linker design. MAbs, 2011.
3(5): p. 487-94 DOI: 10.4161/mabs.3.5.16326.
Wu, C., et al., Simultaneous targeting of multiple disease mediators by a dual-variabledomain immunoglobulin. Nat Biotechnol, 2007. 25(11): p. 1290-7 DOI: 10.1038/nbt1345.
Wu, C., et al., Molecular construction and optimization of anti-human IL-1alpha/beta dual
variable domain immunoglobulin (DVD-Ig) molecules. MAbs, 2009. 1(4): p. 339-47 DOI:
10.4161/mabs.1.4.8755.
Ma, J., et al., Bispecific Antibodies: From Research to Clinical Application. Front Immunol,
2021. 12: p. 626616 DOI: 10.3389/fimmu.2021.626616.
Krah, S., et al., Engineering IgG-Like Bispecific Antibodies-An Overview. Antibodies (Basel),
2018. 7(3) DOI: 10.3390/antib7030028.
Ridgway, J.B., L.G. Presta, and P. Carter, 'Knobs-into-holes' engineering of antibody CH3
domains for heavy chain heterodimerization. Protein Eng, 1996. 9(7): p. 617-21 DOI:
10.1093/protein/9.7.617.
Liu, H., et al., Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel
Scaffolds. Front Immunol, 2017. 8: p. 38 DOI: 10.3389/fimmu.2017.00038.
Gao, W., et al., Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for
Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. Front Physiol, 2017.
8: p. 508 DOI: 10.3389/fphys.2017.00508.
Farooq, M., et al., Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Front Cell Dev Biol, 2021. 9: p. 756315 DOI: 10.3389/fcell.2021.756315.
Monnet, E., et al., Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal
antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a
phase II study. Ann Rheum Dis, 2020. 79(3): p. 316-323 DOI: 10.1136/annrheumdis-2019216487.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
Uematsu, S. and S. Akira, Toll-like receptors and Type I interferons. J Biol Chem, 2007.
282(21): p. 15319-23 DOI: 10.1074/jbc.R700009200.
Kawai, T. and S. Akira, The roles of TLRs, RLRs and NLRs in pathogen recognition. Int
Immunol, 2009. 21(4): p. 317-37 DOI: 10.1093/intimm/dxp017.
Ain, Q.U., M. Batool, and S. Choi, TLR4-Targeting Therapeutics: Structural Basis and
Computer-Aided Drug Discovery Approaches. Molecules, 2020. 25(3) DOI:
10.3390/molecules25030627.
Ohnishi, H., et al., Structural basis for the multiple interactions of the MyD88 TIR domain in
TLR4 signaling. Proc Natl Acad Sci U S A, 2009. 106(25): p. 10260-5 DOI:
10.1073/pnas.0812956106.
Schneider, W.M., M.D. Chevillotte, and C.M. Rice, Interferon-stimulated genes: a complex
web of host defenses. Annu Rev Immunol, 2014. 32: p. 513-45 DOI: 10.1146/annurevimmunol-032713-120231.
Parameswaran, N. and S. Patial, Tumor necrosis factor-alpha signaling in macrophages. Crit
Rev
Eukaryot
Gene
Expr,
2010.
20(2):
p.
87-103
DOI:
10.1615/critreveukargeneexpr.v20.i2.10.
Jang, D.I., et al., The Role of Tumor Necrosis Factor Alpha (TNF-alpha) in Autoimmune
Disease and Current TNF-alpha Inhibitors in Therapeutics. Int J Mol Sci, 2021. 22(5) DOI:
10.3390/ijms22052719.
Kaur, S., et al., A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.
Bioorg Med Chem, 2020. 28(5): p. 115327 DOI: 10.1016/j.bmc.2020.115327.
Singer, M., et al., The Third International Consensus Definitions for Sepsis and Septic Shock
(Sepsis-3). JAMA, 2016. 315(8): p. 801-10 DOI: 10.1001/jama.2016.0287.
Honda, S., et al., Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion
induced by Fcalpha/muR-coupled TLR4 signalling. Nat Commun, 2016. 7: p. 11498 DOI:
10.1038/ncomms11498.
Leon, L.R., A.A. White, and M.J. Kluger, Role of IL-6 and TNF in thermoregulation and
survival during sepsis in mice. Am J Physiol, 1998. 275(1): p. R269-77 DOI:
10.1152/ajpregu.1998.275.1.R269.
Qiu, P., et al., The evolving experience with therapeutic TNF inhibition in sepsis: considering
the potential influence of risk of death. Expert Opin Investig Drugs, 2011. 20(11): p. 1555-64
DOI: 10.1517/13543784.2011.623125.
Chaudhry, H., et al., Role of cytokines as a double-edged sword in sepsis. In Vivo, 2013. 27(6):
p. 669-84.
Hreggvidsdottir, H.S., et al., The alarmin HMGB1 acts in synergy with endogenous and
exogenous danger signals to promote inflammation. J Leukoc Biol, 2009. 86(3): p. 655-62
DOI: 10.1189/jlb.0908548.
Jarczak, D., S. Kluge, and A. Nierhaus, Sepsis-Pathophysiology and Therapeutic Concepts.
Front Med (Lausanne), 2021. 8: p. 628302 DOI: 10.3389/fmed.2021.628302.
Hotchkiss, R.S., et al., Immune checkpoint inhibition in sepsis: a Phase 1b randomized study
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.
Intensive Care Med, 2019. 45(10): p. 1360-1371 DOI: 10.1007/s00134-019-05704-z.
Roger, T., et al., Protection from lethal gram-negative bacterial sepsis by targeting Toll-like
receptor 4. Proc Natl Acad Sci U S A, 2009. 106(7): p. 2348-52 DOI:
10.1073/pnas.0808146106.
Alves-Filho, J.C., et al., Regulation of chemokine receptor by Toll-like receptor 2 is critical to
neutrophil migration and resistance to polymicrobial sepsis. Proc Natl Acad Sci U S A, 2009.
106(10): p. 4018-23 DOI: 10.1073/pnas.0900196106.
Alves-Filho, J.C., et al., Toll-like receptor 4 signaling leads to neutrophil migration
impairment in polymicrobial sepsis. Crit Care Med, 2006. 34(2): p. 461-70 DOI:
10.1097/01.ccm.0000198527.71819.e1.
Casaletto, J.B., et al., MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent
and HGF-independent Met signaling through concurrent binding to EpCAM. Proc Natl Acad
Sci U S A, 2019. 116(15): p. 7533-7542 DOI: 10.1073/pnas.1819085116.
Valanne, S., J.H. Wang, and M. Rämet, The Drosophila Toll signaling pathway. J Immunol,
2011. 186(2): p. 649-56 DOI: 10.4049/jimmunol.1002302.
Molteni, M., S. Gemma, and C. Rossetti, The Role of Toll-Like Receptor 4 in Infectious and
Noninfectious Inflammation. 2016. 2016: p. 6978936 DOI: 10.1155/2016/6978936.
Sha, T., Y. Iizawa, and M. Ii, Combination of imipenem and TAK-242, a Toll-like receptor 4
signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis.
Shock, 2011. 35(2): p. 205-9 DOI: 10.1097/SHK.0b013e3181f48942.
Rusai, K., et al., Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr
Nephrol, 2010. 25(5): p. 853-60 DOI: 10.1007/s00467-009-1422-4.
Jeyaseelan, S., et al., Distinct roles of pattern recognition receptors CD14 and Toll-like
receptor 4 in acute lung injury. Infect Immun, 2005. 73(3): p. 1754-63 DOI:
10.1128/iai.73.3.1754-1763.2005.
Schroder, K., et al., Conservation and divergence in Toll-like receptor 4-regulated gene
expression in primary human versus mouse macrophages. Proc Natl Acad Sci U S A, 2012.
109(16): p. E944-53 DOI: 10.1073/pnas.1110156109.
Zhang, Z., et al., Toll-like receptor 4 signaling in dysfunction of cardiac microvascular
endothelial cells under hypoxia/reoxygenation. Inflamm Res, 2011. 60(1): p. 37-45 DOI:
10.1007/s00011-010-0232-2.
Zhou, S., G. Wang, and W. Zhang, Effect of TLR4/MyD88 signaling pathway on sepsisassociated acute respiratory distress syndrome in rats, via regulation of macrophage
activation and inflammatory response. Experimental and therapeutic medicine, 2018. 15(4):
p. 3376-3384 DOI: 10.3892/etm.2018.5815.
Heuff, G., et al., Isolation of cytotoxic Kupffer cells by a modified enzymatic assay: a
methodological study. J Immunol Methods, 1993. 159(1-2): p. 115-23 DOI: 10.1016/00221759(93)90148-z.
Bachman, J., Reverse-transcription PCR (RT-PCR). Methods Enzymol, 2013. 530: p. 67-74
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
DOI: 10.1016/b978-0-12-420037-1.00002-6.
Jones, S.T. and M.M. Bendig, Rapid PCR-cloning of full-length mouse immunoglobulin
variable regions. Biotechnology (N Y), 1991. 9(1): p. 88-9 DOI: 10.1038/nbt0191-88.
Kabat, E.A., Sequences of proteins of immunological interest. 5th ed. ed. NIH publication.
Vol. no. 91-3242. 1991: National Institutes of Health. 3 v. (xcvi, 2597 p.).
Chothia, C. and A.M. Lesk, Canonical structures for the hypervariable regions of
immunoglobulins. J Mol Biol, 1987. 196(4): p. 901-17 DOI: 10.1016/0022-2836(87)90412-8.
Isaacs, J.D. and H. Waldmann, Helplessness as a strategy for avoiding antiglobulin responses
to therapeutic monoclonal antibodies. Ther Immunol, 1994. 1(6): p. 303-12.
Durrant, L.G., et al., Abrogation of antibody responses in rats to murine monoclonal antibody
791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates. Cancer Immunol
Immunother, 1989. 28(1): p. 37-42 DOI: 10.1007/bf00205799.
Gómez-Mantilla, J.D., et al., Review on modeling anti-antibody responses to monoclonal
antibodies. J Pharmacokinet Pharmacodyn, 2014. 41(5): p. 523-36 DOI: 10.1007/s10928014-9367-z.
Muyldermans, S., Nanobodies: natural single-domain antibodies. Annu Rev Biochem, 2013.
82: p. 775-97 DOI: 10.1146/annurev-biochem-063011-092449.
Strohl, W.R., Antibody discovery: sourcing of monoclonal antibody variable domains. Curr
Drug Discov Technol, 2014. 11(1): p. 3-19 DOI: 10.2174/1570163810666131120150043.
Bujotzek, A., et al., VH-VL orientation prediction for antibody humanization candidate
selection: A case study. MAbs, 2016. 8(2): p. 288-305 DOI: 10.1080/19420862.2015.1117720.
Yang, Y., et al., The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell
Death Dis, 2016. 7(5): p. e2234 DOI: 10.1038/cddis.2016.140.
Degryse, B., et al., The high mobility group (HMG) boxes of the nuclear protein HMG1 induce
chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol, 2001.
152(6): p. 1197-206 DOI: 10.1083/jcb.152.6.1197.
Hreggvidsdottir, H.S., et al., The alarmin HMGB1 acts in synergy with endogenous and
exogenous danger signals to promote inflammation. J Leukoc Biol, 2009. 86(3): p. 655-62
DOI: 10.1189/jlb.0908548.
Lu, Y., et al., Toll-like Receptors and Inflammatory Bowel Disease. Front Immunol, 2018. 9:
p. 72 DOI: 10.3389/fimmu.2018.00072.
Gritte, R.B., et al., Why Septic Patients Remain Sick After Hospital Discharge? Front
Immunol, 2020. 11: p. 605666 DOI: 10.3389/fimmu.2020.605666.
Evans, L., et al., Surviving sepsis campaign: international guidelines for management of
sepsis and septic shock 2021. Intensive Care Med, 2021. 47(11): p. 1181-1247 DOI:
10.1007/s00134-021-06506-y.
Castoldi, A., et al., TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil
migration in acute kidney injury induced by sepsis. PLoS One, 2012. 7(5): p. e37584 DOI:
10.1371/journal.pone.0037584.
Spiller, S., et al., TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Gram-negative sepsis in mice. J Exp Med, 2008. 205(8): p. 1747-54 DOI:
10.1084/jem.20071990.
Fudenberg, H.H., G. Drews, and A. Nisonoff, SEROLOGIC DEMONSTRATION OF DUAL
SPECIFICITY OF RABBIT BIVALENT HYBRID ANTIBODY. J Exp Med, 1964. 119(1): p.
151-66 DOI: 10.1084/jem.119.1.151.
Franquiz, M.J. and N.J. Short, Blinatumomab for the Treatment of Adult B-Cell Acute
Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy. Biologics, 2020.
14: p. 23-34 DOI: 10.2147/btt.s202746.
Labrijn, A.F. and M.L. Janmaat, Bispecific antibodies: a mechanistic review of the pipeline.
2019. 18(8): p. 585-608 DOI: 10.1038/s41573-019-0028-1.
Sato, M., et al., Novel TLR2xTLR4 Bispecific Antibody Inhibits Bacterial Sepsis. Monoclon
Antib Immunodiagn Immunother, 2021. 40(1): p. 6-10 DOI: 10.1089/mab.2020.0025.
Carter, P., et al., Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc
Natl Acad Sci U S A, 1992. 89(10): p. 4285-9 DOI: 10.1073/pnas.89.10.4285.
Presta, L.G., et al., Humanization of an antibody directed against IgE. J Immunol, 1993.
151(5): p. 2623-32.
Ewert, S., A. Honegger, and A. Plückthun, Stability improvement of antibodies for
extracellular and intracellular applications: CDR grafting to stable frameworks and
structure-based framework engineering. Methods, 2004. 34(2): p. 184-99 DOI:
10.1016/j.ymeth.2004.04.007.
Umemura, Y., et al., Current spectrum of causative pathogens in sepsis: A prospective
nationwide cohort study in Japan. Int J Infect Dis, 2021. 103: p. 343-351 DOI:
10.1016/j.ijid.2020.11.168.
Rappazzo, C.G. and L.V. Tse, Broad and potent activity against SARS-like viruses by an
engineered human monoclonal antibody. 2021. 371(6531): p. 823-829 DOI:
10.1126/science.abf4830.
Dunn-Siegrist, I., et al., Pivotal involvement of Fcgamma receptor IIA in the neutralization of
lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol
Chem, 2007. 282(48): p. 34817-27 DOI: 10.1074/jbc.M706440200.
Rhoden, J.J., G.L. Dyas, and V.J. Wroblewski, A Modeling and Experimental Investigation of
the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific
Antibody Binding to Cell Surface Targets. 2016. 291(21): p. 11337-47 DOI:
10.1074/jbc.M116.714287.
Bruhns, P., et al., Specificity and affinity of human Fcgamma receptors and their polymorphic
variants for human IgG subclasses. Blood, 2009. 113(16): p. 3716-25 DOI: 10.1182/blood2008-09-179754.
Boontham, P., et al., Surgical sepsis: dysregulation of immune function and therapeutic
implications. Surgeon, 2003. 1(4): p. 187-206 DOI: 10.1016/s1479-666x(03)80018-5.
Gopalakrishnan, M., et al., Ligand rebinding: self-consistent mean-field theory and numerical
simulations applied to surface plasmon resonance studies. Eur Biophys J, 2005. 34(7): p. 9438
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
58 DOI: 10.1007/s00249-005-0471-2.
Douzi, B., Protein-Protein Interactions: Surface Plasmon Resonance. Methods Mol Biol,
2017. 1615: p. 257-275 DOI: 10.1007/978-1-4939-7033-9_21.
Kamat, V. and A. Rafique, Designing binding kinetic assay on the bio-layer interferometry
(BLI) biosensor to characterize antibody-antigen interactions. Anal Biochem, 2017. 536: p.
16-31 DOI: 10.1016/j.ab.2017.08.002.
Hadzhieva, M., et al., Impact of Antigen Density on the Binding Mechanism of IgG Antibodies.
Sci Rep, 2017. 7(1): p. 3767 DOI: 10.1038/s41598-017-03942-z.
Klein, J.S. and P.J. Bjorkman, Few and far between: how HIV may be evading antibody avidity.
PLoS Pathog, 2010. 6(5): p. e1000908 DOI: 10.1371/journal.ppat.1000908.
Barbas, C.F., 3rd, et al., In vitro evolution of a neutralizing human antibody to human
immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc
Natl Acad Sci U S A, 1994. 91(9): p. 3809-13 DOI: 10.1073/pnas.91.9.3809.
Roost, H.P., et al., Early high-affinity neutralizing anti-viral IgG responses without further
overall improvements of affinity. Proc Natl Acad Sci U S A, 1995. 92(5): p. 1257-61 DOI:
10.1073/pnas.92.5.1257.
Mouquet, H., et al., Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl
Acad Sci U S A, 2012. 109(3): p. 875-80 DOI: 10.1073/pnas.1120059109.
Kim, H.S., et al., Sulfatide Inhibits HMGB1 Secretion by Hindering Toll-Like Receptor 4
Localization Within Lipid Rafts. Front Immunol, 2020. 11: p. 1305 DOI:
10.3389/fimmu.2020.01305.
Kataoka, H., et al., Naringenin suppresses Toll-like receptor 2-mediated inflammatory
responses through inhibition of receptor clustering on lipid rafts. Food Sci Nutr, 2021. 9(2):
p. 963-972 DOI: 10.1002/fsn3.2063.
Hung, A.F., et al., Lipid rafts hinder binding of antibodies to the extracellular segment of the
membrane-anchor peptide of mIgA. Mol Immunol, 2011. 48(15-16): p. 1975-82 DOI:
10.1016/j.molimm.2011.06.219.
...
論文の公開元へ
